This roundtable series debates using newer JAK inhibitors as therapy for patients with myelofibrosis, considering the efficacy and safety profiles of the drugs, as discussed by participants at virtual live events.
Reactions to the Latest Data on JAK Inhibition for MyelofibrosisOctober 12th 2022
During a live virtual event, John O. Mascarenhas, MD, discussed with participants the data supporting the use of pacritinib for patients with myelofibrosis. This is the second of 2 articles based on this event.
Introducing Pacritinib into Treatment Plans for MyelofibrosisNovember 21st 2022
During a Targeted Oncology case-based roundtable event, Jeanne M. Palmer, MD, discussed with participants how the approval of pacritinib for patients with myelofibrosis affects their treatment approach.